Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 76Recruiting 34Terminated 18Active not recruiting 17Withdrawn 5Not yet recruiting 3Enrolling by invitation 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

zilucoplan 1toripalimab 1somapacitan 1rozanolixizumab 1pembrolizumab 1ibrutinib 1futibatinib 1exemestane 1enzalutamide 1durvalumab 1decitabine and cedazuridine drug combination 1cemiplimab 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Tamoxifen 1Robotic Surgical Procedures 1Observation 1Letrozole 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Fulvestrant 1Folfox protocol 1Dexamethasone 1Cisplatin 1Carboplatin 1Bevacizumab 1Anastrozole 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × INDUSTRY × enzalutamide × Clear all
NCT04145375 2026-05-08

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Zenith Epigenetics

Phase 1/2 Enrolling by invitation
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡